FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants.

Abstract	On December 13, 2002, the U.S. Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), hepatitis B (HepB) (recombinant) and inactivated poliovirus vaccine (IPV), DTaP-HepB-IPV (PEDIARIX, SmithKline Beecham Biologicals, Rixensart, Belgium) for use in infants ages 2, 4, and 6 months. All components in the combined vaccine are recommended for routine use by the Advisory Committee on Immunization Practices (ACIP), the Committee on Infectious Diseases of the American Academy of Pediatrics, and the American Academy of Family Physicians. Combination vaccines decrease the number of vaccine injections.
Authors	Centers for Disease Control and Prevention (CDC)
Journal	MMWR. Morbidity and mortality weekly report (MMWR Morb Mortal Wkly Rep) Vol. 52 Issue 10 Pg. 203-4 (Mar 14 2003) ISSN: 0149-2195 [Print] United States
PMID	12653460 (Publication Type: Journal Article)
Chemical References	Diphtheria-Tetanus-Pertussis Vaccine Diphtheria-Tetanus-acellular Pertussis Vaccines Hepatitis B Vaccines PEDIARIX Poliovirus Vaccine, Inactivated Vaccines, Combined
Topics	Diphtheria-Tetanus-Pertussis Vaccine Diphtheria-Tetanus-acellular Pertussis Vaccines Hepatitis B Vaccines Humans Immunization Programs Immunization Schedule Infant Poliovirus Vaccine, Inactivated United States United States Food and Drug Administration Vaccines, Combined (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!